Radioligand-Binding Assay Employing P-Glycoprotein-Overexpressing Cells: Testing Drug Affinities to the Secretory Intestinal Multidrug Transporter View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-07

AUTHORS

Stephan Döppenschmitt, Hildegard Spahn-Langguth, Carl Gunnar Regårdh, Peter Langguth

ABSTRACT

PURPOSE: To develop a rapid and reliable system for affinity determination of conventional as well as newly synthesized compounds to P-gp. METHODS: The principles of radioligand-binding assay were adapted to the human intestinal P-gp. Acceptor protein was obtained from the human carcinoma cell line Caco-2, where overexpression of P-gp was induced by growing cells in the presence of the cytostatic drug vinblastine. 3H-Verapamil was chosen as radioligand. RESULTS: The saturability and specificity of 3H-verapamil as the radioligand for the binding to P-gp was demonstrated. From concentration dependence of displacement of the radioligand by various non-labeled ligands for P-gp, affinity constants to P-gp binding sites were calculated. The binding results obtained were in agreement with those published earlier where influx and efflux experiments with cell monolayers had been conducted in order to functionally characterize the P-gp -drug interaction. CONCLUSIONS: A radioligand-binding assay on the basis of P-gp overexpressing Caco-2 cells has been developed. The method might be suitable for high-throughput screening of drug interaction with human P-gp. It will allow modeling of the interaction of drugs with the human multidrug transporter and has also the potential to serve as a high-throughput screening tool to detect compounds prone to P-gp mediated intestinal secretion and potential P-gp related drug/drug interactions in drug discovery and early development. More... »

PAGES

1001-1006

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1011965707998

DOI

http://dx.doi.org/10.1023/a:1011965707998

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009023493

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9688051


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP-Binding Cassette, Sub-Family B, Member 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Phytogenic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Binding, Competitive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caco-2 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium Channel Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorescent Dyes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Propanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radioligand Assay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reproducibility of Results", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rhodamine 123", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rhodamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tritium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Verapamil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vinblastine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca (Sweden)", 
          "id": "https://www.grid.ac/institutes/grid.418151.8", 
          "name": [
            "School of Pharmacy, Martin-Luther-Universit\u00e4t Halle Wittenberg, Wolfgang-Langenbeck-Strasse 4, D-06120, Halle (Saale), Germany", 
            "ASTRA H\u00c4SSLE AB, PKDM, S-431 83, M\u00f6lndal, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u00f6ppenschmitt", 
        "givenName": "Stephan", 
        "id": "sg:person.0772045316.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772045316.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Martin Luther University Halle-Wittenberg", 
          "id": "https://www.grid.ac/institutes/grid.9018.0", 
          "name": [
            "School of Pharmacy, Martin-Luther-Universit\u00e4t Halle Wittenberg, Wolfgang-Langenbeck-Strasse 4, D-06120, Halle (Saale), Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spahn-Langguth", 
        "givenName": "Hildegard", 
        "id": "sg:person.01052720414.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052720414.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (Sweden)", 
          "id": "https://www.grid.ac/institutes/grid.418151.8", 
          "name": [
            "ASTRA H\u00c4SSLE AB, PKDM, S-431 83, M\u00f6lndal, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reg\u00e5rdh", 
        "givenName": "Carl Gunnar", 
        "id": "sg:person.0107564625.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0107564625.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (Sweden)", 
          "id": "https://www.grid.ac/institutes/grid.418151.8", 
          "name": [
            "ASTRA H\u00c4SSLE AB, PKDM, S-431 83, M\u00f6lndal, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Langguth", 
        "givenName": "Peter", 
        "id": "sg:person.0727014114.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727014114.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0006-291x(90)90786-m", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000504453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0731-7085(86)80081-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001243287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02110329", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002663694", 
          "https://doi.org/10.1007/bf02110329"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02110329", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002663694", 
          "https://doi.org/10.1007/bf02110329"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(94)90187-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003075166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0169-409x(97)00497-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011952235"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.84.21.7735", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012281167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1432-1033.1997.0219a.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013567092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.85.10.3580", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024159868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024399060", 
          "https://doi.org/10.1007/bf00685648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024399060", 
          "https://doi.org/10.1007/bf00685648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1993.tb13914.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025857760"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0009-9236(96)90182-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030380188", 
          "https://doi.org/10.1016/s0009-9236(96)90182-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.pa.20.040180.003053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042227977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/abbi.1995.1020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043272391"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1016029601311", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044138980", 
          "https://doi.org/10.1023/a:1016029601311"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015984626848", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050173344", 
          "https://doi.org/10.1023/a:1015984626848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075763080", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1096/fasebj.8.10.7914178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082562986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082649050", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082651259", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2144/96205st02", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082927054"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083215842", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-07", 
    "datePublishedReg": "1998-07-01", 
    "description": "PURPOSE: To develop a rapid and reliable system for affinity determination of conventional as well as newly synthesized compounds to P-gp.\nMETHODS: The principles of radioligand-binding assay were adapted to the human intestinal P-gp. Acceptor protein was obtained from the human carcinoma cell line Caco-2, where overexpression of P-gp was induced by growing cells in the presence of the cytostatic drug vinblastine. 3H-Verapamil was chosen as radioligand.\nRESULTS: The saturability and specificity of 3H-verapamil as the radioligand for the binding to P-gp was demonstrated. From concentration dependence of displacement of the radioligand by various non-labeled ligands for P-gp, affinity constants to P-gp binding sites were calculated. The binding results obtained were in agreement with those published earlier where influx and efflux experiments with cell monolayers had been conducted in order to functionally characterize the P-gp -drug interaction.\nCONCLUSIONS: A radioligand-binding assay on the basis of P-gp overexpressing Caco-2 cells has been developed. The method might be suitable for high-throughput screening of drug interaction with human P-gp. It will allow modeling of the interaction of drugs with the human multidrug transporter and has also the potential to serve as a high-throughput screening tool to detect compounds prone to P-gp mediated intestinal secretion and potential P-gp related drug/drug interactions in drug discovery and early development.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1011965707998", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Radioligand-Binding Assay Employing P-Glycoprotein-Overexpressing Cells: Testing Drug Affinities to the Secretory Intestinal Multidrug Transporter", 
    "pagination": "1001-1006", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2afd071ef1772a0c99710cc08a9becb18fb6b4f6c2dc9408faa03b5e68e5dc21"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9688051"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8406521"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1011965707998"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009023493"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1011965707998", 
      "https://app.dimensions.ai/details/publication/pub.1009023493"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T23:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000498.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/A:1011965707998"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1011965707998'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1011965707998'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1011965707998'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1011965707998'


 

This table displays all metadata directly associated to this object as RDF triples.

226 TRIPLES      21 PREDICATES      67 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1011965707998 schema:about N0ebcc2bed10d4f15abfb10a6329eac45
2 N148a36b73d9f42339e0e836c86e47a2c
3 N2314fc242b83407ca8a26a6d8591e54c
4 N4f100851114d43ef9f4d092d5f4b7afe
5 N60f94da8e243428cae8e32b15d464aea
6 N63f06586fb81402fafb47cd1903a58d5
7 N765ba4caa06c447581acb6b32aef0663
8 N9a8e775ecc9c4416811ec4a2bf0fb6d1
9 Na0a6c1928d0a43c4957b87184a548d0f
10 Nc324197ff0364b52890ca151bfde2ff3
11 Nc537e6ed062d463d97a6b85ade5a6510
12 Nc9f49e8796e042a9abdb3c37cc380e11
13 Nca22cb5767f145b9bc34f6ec39d0b8c3
14 Nd91a80d37b374e1494a92f41d912ed4d
15 Neda62e023e7440f2bd80e3cc88d17f32
16 Nf385e943fec24f39aeb6d589ea219572
17 Nffab62113e3d4c0eae24fd6d72865703
18 anzsrc-for:11
19 anzsrc-for:1115
20 schema:author Ne8df070ce3e6464e8ac57d2149405b73
21 schema:citation sg:pub.10.1007/bf00685648
22 sg:pub.10.1007/bf02110329
23 sg:pub.10.1016/s0009-9236(96)90182-4
24 sg:pub.10.1023/a:1015984626848
25 sg:pub.10.1023/a:1016029601311
26 https://app.dimensions.ai/details/publication/pub.1075763080
27 https://app.dimensions.ai/details/publication/pub.1082649050
28 https://app.dimensions.ai/details/publication/pub.1082651259
29 https://app.dimensions.ai/details/publication/pub.1083215842
30 https://doi.org/10.1006/abbi.1995.1020
31 https://doi.org/10.1016/0006-291x(90)90786-m
32 https://doi.org/10.1016/0731-7085(86)80081-4
33 https://doi.org/10.1016/0959-8049(94)90187-2
34 https://doi.org/10.1016/s0169-409x(97)00497-3
35 https://doi.org/10.1073/pnas.84.21.7735
36 https://doi.org/10.1073/pnas.85.10.3580
37 https://doi.org/10.1096/fasebj.8.10.7914178
38 https://doi.org/10.1111/j.1432-1033.1997.0219a.x
39 https://doi.org/10.1111/j.1476-5381.1993.tb13914.x
40 https://doi.org/10.1146/annurev.pa.20.040180.003053
41 https://doi.org/10.2144/96205st02
42 schema:datePublished 1998-07
43 schema:datePublishedReg 1998-07-01
44 schema:description PURPOSE: To develop a rapid and reliable system for affinity determination of conventional as well as newly synthesized compounds to P-gp. METHODS: The principles of radioligand-binding assay were adapted to the human intestinal P-gp. Acceptor protein was obtained from the human carcinoma cell line Caco-2, where overexpression of P-gp was induced by growing cells in the presence of the cytostatic drug vinblastine. 3H-Verapamil was chosen as radioligand. RESULTS: The saturability and specificity of 3H-verapamil as the radioligand for the binding to P-gp was demonstrated. From concentration dependence of displacement of the radioligand by various non-labeled ligands for P-gp, affinity constants to P-gp binding sites were calculated. The binding results obtained were in agreement with those published earlier where influx and efflux experiments with cell monolayers had been conducted in order to functionally characterize the P-gp -drug interaction. CONCLUSIONS: A radioligand-binding assay on the basis of P-gp overexpressing Caco-2 cells has been developed. The method might be suitable for high-throughput screening of drug interaction with human P-gp. It will allow modeling of the interaction of drugs with the human multidrug transporter and has also the potential to serve as a high-throughput screening tool to detect compounds prone to P-gp mediated intestinal secretion and potential P-gp related drug/drug interactions in drug discovery and early development.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree false
48 schema:isPartOf N22997f8aba0547f6833108acd4d0c9de
49 Nc5a104a02f3b453daf13c02f1eac843a
50 sg:journal.1094644
51 schema:name Radioligand-Binding Assay Employing P-Glycoprotein-Overexpressing Cells: Testing Drug Affinities to the Secretory Intestinal Multidrug Transporter
52 schema:pagination 1001-1006
53 schema:productId N03b3af7f58244c28973682a5309165cc
54 N1898155ce0514ded897da1792b50ec54
55 N3e588623ac284d46a552bbefe4d0fd64
56 N55d3c2d10e97442288c96ec5fba3d5ba
57 N84c8b8d9630b42eb9b84097c7f268c27
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009023493
59 https://doi.org/10.1023/a:1011965707998
60 schema:sdDatePublished 2019-04-10T23:21
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N726c76fda84b44798a66d3ecad58ab5a
63 schema:url http://link.springer.com/10.1023/A:1011965707998
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N03b3af7f58244c28973682a5309165cc schema:name doi
68 schema:value 10.1023/a:1011965707998
69 rdf:type schema:PropertyValue
70 N0ebcc2bed10d4f15abfb10a6329eac45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Binding, Competitive
72 rdf:type schema:DefinedTerm
73 N148a36b73d9f42339e0e836c86e47a2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Propanolamines
75 rdf:type schema:DefinedTerm
76 N18270e6dad004c1eaefcc3b1bb63d66f rdf:first sg:person.01052720414.09
77 rdf:rest Ne07f6c85276e4bcd9d500143fd5f7b4a
78 N1898155ce0514ded897da1792b50ec54 schema:name dimensions_id
79 schema:value pub.1009023493
80 rdf:type schema:PropertyValue
81 N22997f8aba0547f6833108acd4d0c9de schema:volumeNumber 15
82 rdf:type schema:PublicationVolume
83 N2314fc242b83407ca8a26a6d8591e54c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Kinetics
85 rdf:type schema:DefinedTerm
86 N3e588623ac284d46a552bbefe4d0fd64 schema:name nlm_unique_id
87 schema:value 8406521
88 rdf:type schema:PropertyValue
89 N4f100851114d43ef9f4d092d5f4b7afe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Rhodamines
91 rdf:type schema:DefinedTerm
92 N55d3c2d10e97442288c96ec5fba3d5ba schema:name readcube_id
93 schema:value 2afd071ef1772a0c99710cc08a9becb18fb6b4f6c2dc9408faa03b5e68e5dc21
94 rdf:type schema:PropertyValue
95 N60f94da8e243428cae8e32b15d464aea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Calcium Channel Blockers
97 rdf:type schema:DefinedTerm
98 N63f06586fb81402fafb47cd1903a58d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Rhodamine 123
100 rdf:type schema:DefinedTerm
101 N726c76fda84b44798a66d3ecad58ab5a schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 N765ba4caa06c447581acb6b32aef0663 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name ATP-Binding Cassette, Sub-Family B, Member 1
105 rdf:type schema:DefinedTerm
106 N84c8b8d9630b42eb9b84097c7f268c27 schema:name pubmed_id
107 schema:value 9688051
108 rdf:type schema:PropertyValue
109 N9071987329f54fe9bd945e741c7845f2 rdf:first sg:person.0727014114.39
110 rdf:rest rdf:nil
111 N9a8e775ecc9c4416811ec4a2bf0fb6d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Tritium
113 rdf:type schema:DefinedTerm
114 Na0a6c1928d0a43c4957b87184a548d0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Adrenergic beta-Antagonists
116 rdf:type schema:DefinedTerm
117 Nc324197ff0364b52890ca151bfde2ff3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Verapamil
119 rdf:type schema:DefinedTerm
120 Nc537e6ed062d463d97a6b85ade5a6510 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Reproducibility of Results
122 rdf:type schema:DefinedTerm
123 Nc5a104a02f3b453daf13c02f1eac843a schema:issueNumber 7
124 rdf:type schema:PublicationIssue
125 Nc9f49e8796e042a9abdb3c37cc380e11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Vinblastine
127 rdf:type schema:DefinedTerm
128 Nca22cb5767f145b9bc34f6ec39d0b8c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Radioligand Assay
130 rdf:type schema:DefinedTerm
131 Nd91a80d37b374e1494a92f41d912ed4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Antineoplastic Agents, Phytogenic
133 rdf:type schema:DefinedTerm
134 Ne07f6c85276e4bcd9d500143fd5f7b4a rdf:first sg:person.0107564625.16
135 rdf:rest N9071987329f54fe9bd945e741c7845f2
136 Ne8df070ce3e6464e8ac57d2149405b73 rdf:first sg:person.0772045316.55
137 rdf:rest N18270e6dad004c1eaefcc3b1bb63d66f
138 Neda62e023e7440f2bd80e3cc88d17f32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Fluorescent Dyes
140 rdf:type schema:DefinedTerm
141 Nf385e943fec24f39aeb6d589ea219572 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Nffab62113e3d4c0eae24fd6d72865703 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Caco-2 Cells
146 rdf:type schema:DefinedTerm
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
151 schema:name Pharmacology and Pharmaceutical Sciences
152 rdf:type schema:DefinedTerm
153 sg:journal.1094644 schema:issn 0724-8741
154 1573-904X
155 schema:name Pharmaceutical Research
156 rdf:type schema:Periodical
157 sg:person.01052720414.09 schema:affiliation https://www.grid.ac/institutes/grid.9018.0
158 schema:familyName Spahn-Langguth
159 schema:givenName Hildegard
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052720414.09
161 rdf:type schema:Person
162 sg:person.0107564625.16 schema:affiliation https://www.grid.ac/institutes/grid.418151.8
163 schema:familyName Regårdh
164 schema:givenName Carl Gunnar
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0107564625.16
166 rdf:type schema:Person
167 sg:person.0727014114.39 schema:affiliation https://www.grid.ac/institutes/grid.418151.8
168 schema:familyName Langguth
169 schema:givenName Peter
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727014114.39
171 rdf:type schema:Person
172 sg:person.0772045316.55 schema:affiliation https://www.grid.ac/institutes/grid.418151.8
173 schema:familyName Döppenschmitt
174 schema:givenName Stephan
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772045316.55
176 rdf:type schema:Person
177 sg:pub.10.1007/bf00685648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024399060
178 https://doi.org/10.1007/bf00685648
179 rdf:type schema:CreativeWork
180 sg:pub.10.1007/bf02110329 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002663694
181 https://doi.org/10.1007/bf02110329
182 rdf:type schema:CreativeWork
183 sg:pub.10.1016/s0009-9236(96)90182-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030380188
184 https://doi.org/10.1016/s0009-9236(96)90182-4
185 rdf:type schema:CreativeWork
186 sg:pub.10.1023/a:1015984626848 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050173344
187 https://doi.org/10.1023/a:1015984626848
188 rdf:type schema:CreativeWork
189 sg:pub.10.1023/a:1016029601311 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044138980
190 https://doi.org/10.1023/a:1016029601311
191 rdf:type schema:CreativeWork
192 https://app.dimensions.ai/details/publication/pub.1075763080 schema:CreativeWork
193 https://app.dimensions.ai/details/publication/pub.1082649050 schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1082651259 schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1083215842 schema:CreativeWork
196 https://doi.org/10.1006/abbi.1995.1020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043272391
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/0006-291x(90)90786-m schema:sameAs https://app.dimensions.ai/details/publication/pub.1000504453
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/0731-7085(86)80081-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001243287
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/0959-8049(94)90187-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003075166
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/s0169-409x(97)00497-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011952235
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1073/pnas.84.21.7735 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012281167
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1073/pnas.85.10.3580 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024159868
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1096/fasebj.8.10.7914178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082562986
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1111/j.1432-1033.1997.0219a.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1013567092
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1111/j.1476-5381.1993.tb13914.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025857760
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1146/annurev.pa.20.040180.003053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042227977
217 rdf:type schema:CreativeWork
218 https://doi.org/10.2144/96205st02 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082927054
219 rdf:type schema:CreativeWork
220 https://www.grid.ac/institutes/grid.418151.8 schema:alternateName AstraZeneca (Sweden)
221 schema:name ASTRA HÄSSLE AB, PKDM, S-431 83, Mölndal, Sweden
222 School of Pharmacy, Martin-Luther-Universität Halle Wittenberg, Wolfgang-Langenbeck-Strasse 4, D-06120, Halle (Saale), Germany
223 rdf:type schema:Organization
224 https://www.grid.ac/institutes/grid.9018.0 schema:alternateName Martin Luther University Halle-Wittenberg
225 schema:name School of Pharmacy, Martin-Luther-Universität Halle Wittenberg, Wolfgang-Langenbeck-Strasse 4, D-06120, Halle (Saale), Germany
226 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...